Tokyo (JCN) Dec 26, 2005 - Astellas Pharma announced on December 26 that its US subsidiary Astellas Pharma US has filed a New Drug Application for FK506 modified release formulation (tacrolimus), its proprietary immunosuppressant, with the US Food and Drug Administration (FDA). The subsidiary is seeking approval to use the agent for preventing rejection in patients who have organ transplants. FK 506 (tacrolimus), which was discovered by Astellas Pharma, is now prescribed in about 70 countries worldwide under the trade name of Prograf.
